Genentech has been asked to turn over marketing materials for its cancer drug Rituxan in an event that may signal increasing FDA crackdown of off label marketing. Regardless of the outcome in this particular case, off label drug use raises several interesting ethical issues. This is discussed in this piece in Red Herring. – David Magnus
Labels: cancer drugs, FDA, Genentech, off-label use